During a significant performance briefing, InnoCare Medical disclosed thelatest advancements and far – reaching commercialization objectives of itsQuanZhen AI medical large model. This model, as a core offering, hasdemonstrated remarkable growth in commercialization.
Data from the April 23rd briefing shows that the QuanZhen AI medical largemodel earned 4.4 million yuan in 2024, excluding primary – lEVEl HIS servicerevenues. The company’s future blueprint is even more impressive. In 2024,around 60 hosPitals partnered with the model. In 2025, InnoCare Medicalanticipates adding about 100 more collaborating hospitals, significantlyboosting its medical institution coverage.
With the rapid expansion of its cooperation network , InnoCare Medical ishighly optimistic about the revenue growth of the QuanZhen AI medicallarge model. The company has set a clear 2025 revenue target of 40 millionyuan for the model, nearly ten times the 2024 Figure, reflecting its strongbelief in the product’s commercial potential.
InnoCare Medical is actively driving market promotion and commercialapplication of this AI medical large model, aiming for a leading position inthe competitive AI medical sector. Whether the QuanZhen AI medical large modelcan reach its ambitious commercialization goals in the coming year is yetto be determined.
